Efficacy and Safety of a Chinese Herbal Formula (Invigorating Kidney and Strengthening Spleen) in Chronic Hepatitis B Virus Carrier: Results from a Multicenter, Randomized, Double-Blind, and Placebo-Controlled Trial
Table 3
Baseline characteristics of the total study patients.
Variable
Treatment group ()
Control group ()
values
Age, mean (SD), y
33.34 (6.86)
34.01 (8.32)
0.7415
0.4590#
Range
21–59
22–63
Sex, (%)
0.1904
0.6625※
Male
137 (68.50)
66 (66.00)
Female
63 (31.50)
34 (34.00)
Clinical course, mean (SD), m
86.35 (72.13)
90.56 (70.48)
0.4808
0.6310#
ALT, mean (SD), U/L
26.40 (8.71)
26.57 (7.92)
0.1640
0.8698#
HBV DNA, mean (SD), log10 IU/mL
8.15 (1.13)
8.17 (1.02)
0.1479
0.8825#
HBV DNA baseline level, (%)
5 to <7 log10 IU/mL
28 (14.00)
11 (11.00)
0.5305
0.4664※
7 to <9 log10 IU/mL
141 (70.50)
74 (74.00)
0.4022
0.5260※
>9 log10 IU/mL
31 (15.50)
15 (15.00)
0.0128
0.9098※
HBsAg, mean (SD), log10 IU/mL
4.56 (0.62)
4.60 (0.60)
0.5030
0.6154#
SD: standard deviation; ALT: alanine aminotransferase; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen. ※Chi-square test.
#-test.
